PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1744427
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1744427
Global brain imaging devices market is projected to witness a CAGR of 7.61% during the forecast period 2025-2032, growing from USD 4.98 billion in 2024 to USD 8.95 billion in 2032. The market's growth can be attributed to the increasing prevalence of neurological diseases, rising investments in product innovations and research and development activities, and supportive regulatory frameworks and policies. As per the estimates of the World Health Organization (WHO) over 1 in 3 people across the globe are affected by neurological conditions. The increasing incidences of neurological disorders can be attributed to the rapid expansion of the geriatric population and increasing lifestyle changes.
Continuous innovations and rapid advancements in brain imaging technologies along with integration of machine learning and artificial intelligence (AI) with brain imaging devices are allowing early disease detection. AI-powered tools are being used to automate image interpretation, detect subtle changes invisible to the human eye, and predict disease outcomes based on large datasets. These technologies significantly reduce the workload of healthcare professionals and are boosting diagnostic throughput in busy clinical environments. Furthermore, cloud-based imaging solutions allow remote viewing, tele-neurology consultations, and real-time collaboration, which are especially useful in rural regions. Advancements in wearable EEG devices and portable MRI units are ease of use and improving mobility, increasing user convenience and supporting the market's expansion.
Increasing Focus on Research and Development Boosts Market Growth
Research and development activities are fueling innovations and leading to the development of advanced imaging technologies including functional imaging and high-resolution MRIs, among others. Such innovations allow healthcare professionals to monitor the progression of neurological diseases while meeting the rising requirements for non-invasive and precise diagnostic solutions. Additionally, increasing research efforts are also aiding companies in gaining approvals from different regulatory bodies for their products and technologies, further incentivizing them to invest in product innovation. For instance, in May 2025, Hyperfine, Inc. secured clearance from the United States Food and Drug Administration (US FDA) for the latest version of its Swoop system's Optive AI software. The software is able to refine each stage involved in image processing, from postprocessing, noise cancellation, and reconstruction, to image acquisition. Furthermore, the integration of AI-driven enhancements is reducing scan time, streamlining workflow, and supporting rapid clinical decision making. Such advancements are broadening the utility and reach of brain imaging devices, propelling the market's growth.
Rising Prevalence of Neurological Diseases Supports Market Expansion
Due to the expansion of the geriatric population, the incidences of age-related cognitive disorders including Parkinson's disease and Alzheimer's are rapidly increasing. As per the estimates of the Parkinson's Foundation, over 10 million people across the world are living with Parkinson's disease. Brain imaging is essential for diagnosing, monitoring, and managing such conditions as they often require long-term medical oversight, thus bolstering the market's demand. By integrating functional imaging techniques, such as fMRI and PET, it has become possible to observe not just the brain's structure, but also its metabolic and functional activity, enabling physicians to track disease progression in a more precise manner and tailor treatment strategies accordingly. The continued push toward precision medicine and personalized treatments are bolstering the requirement for detailed, patient-specific brain maps, thus augmenting the requirement for advanced brain imaging technologies.
Devices Account for Significant Share of the Market
Devices, in particular MRIs, hold a major share of the brain imaging devices market. This dominance can be attributed to their ability to provide detailed and high-resolution functional and anatomical images of the brain. The superior image quality provided by MRIs allows clinicians to monitor disease progression and detect subtle abnormalities more effectively. Technological advancements, including integration of AI for conducting image analysis are providing improved diagnostic accuracy, expanding the accessibility of MRI technology, and reducing scan times.
In order to further increase physician and patient convenience, the key players of the market are focusing on introducing new products. For instance, in March 2024, FUJIFILM India Private Limited launched the Echelon Synergy MRI Machine at its CT and MRI User Conclave held at Mumbai, India. The system ensures fast exam times, low power consumption, and features sitting flexibility. Such launches are improving patient convenience and positively influencing the market's expansion.
North America Holds Major Market Share
The region's dominance in the market is supported by the high awareness about neurological conditions, easy acceptance of advanced diagnostic technologies, strong presence of leading market players, and high investments in research and development activities. As per the estimates of Alzheimer's Association, over 7 million people in America are living with Alzheimer's. The number is estimated to increase to 13 million by 2050.
Additionally, the increasing popularity and availability of compact and portable brain imaging devices in the region is enhancing patient convenience and accessibility, making it easier for medical professionals to conduct diagnostic procedures in various settings, including remote locations. Such innovations are improving healthcare delivery across North America and supporting the market's expansion. Increasing public fundings and government initiatives towards neuroscience research, including the BRAIN Initiative are also supporting the market's expansion in countries such as the United States.
Impact of the U.S. Tariff on Global Brain Imaging Devices Market
The recently launched tariffs are affecting imports from major manufacturing hubs including, Mexico, China, and the European Union and have imposed significant economic pressure on healthcare providers and medical device manufacturers and strains on supply chains. The escalation in tariffs is forcing various companies to seek alternative suppliers and reassess their sourcing strategies and focus on enhancing their domestic manufacturing capabilities. The increasing financial strains on medical device companies could potentially lead to reduced investments in research and development activities, slowing down innovations in brain imaging technologies.
Key Players Landscape and Outlook
As the burden of neurological conditions is increasing across the globe, the leading market players are focusing on introducing new technologies to ensure their early and accurate detection. For instance, in February 2024, Koninklijke Philips N.V. in collaboration with SyntheticMR AB launched Smart Quant Neuro 3D for diagnosing brain disorders such as dementia, traumatic brain injury, and multiple sclerosis. Smart Quant Neuro 3D combines Synthetic MR's SyMRI NEURO 3D quantitative tissue assessment software and Philips' AI based SmartSpeed image-reconstruction technology. Smart Quant Neuro 3D is effective in measuring myelin, the layer around nerves responsible for ensuring that electrical impulses reach their destination. Such launches allow medical professionals to accurately diagnose brain disorders in a time efficient manner and aid market players in expanding their global presence.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.